Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358152 | 0.69 | DRD2 (0.58) | DRD2SIGMAR1DRD3NR1H2NR1H3 | |
| SCHEMBL2865406 | 0.69 | DRD2 (0.58) | DRD2SIGMAR1DRD3NR1H2NR1H3 | |
| SCHEMBL4827565 | 0.68 | DRD2 (0.53) | DRD2SIGMAR1DRD3HTR6 | |
| SCHEMBL3318151 | 0.68 | OPRM1 (0.43) | DRD2SIGMAR1HSD11B1DRD3NR1H2 | |
| SCHEMBL612693 | 0.67 | BRD4 (0.41) | CTSSCTSKLOXL2KCNH2BRD4 | |
| SCHEMBL4823982 | 0.66 | HTR2C (0.57) | SIGMAR1HTR6 | |
| SCHEMBL15436281 | 0.66 | DRD2 (0.54) | DRD2SIGMAR1PTGS2DRD3HTR6 | |
| SCHEMBL6243674 | 0.66 | KCNH2 (0.50) | CTSSCTSKLOXL2KCNH2PTGS2 | |
| SCHEMBL15037809 | 0.65 | LOXL2 (0.41) | CTSSCTSKDRD2LOXL2SIGMAR1 | |
| SCHEMBL18396148 | 0.65 | DRD2 (0.49) | DRD2SIGMAR1DRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139525-B2 | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | CTSS 3052/4885CTSK 2552/4885DRD2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.